Takeda terminates GDX012 AML trial by sponsor decision; results posted
Takeda's Phase 1/2a study of cell therapy GDX012 in relapsed or refractory AML was terminated for sponsor decision, not safety, with results posted.
Takeda's registry update this week centers on a single terminated trial for its GDX012 cell therapy program.
- "A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia" (NCT05886491) is a Phase 1/2a, open-label, dose escalation and expansion trial of the allogeneic gamma delta T cell therapy GDX012, also known as TAK-012, in adults with relapsed or refractory AML. The study's overall status is terminated, with the reason listed as sponsor decision and no safety concern noted.1 The trial had planned enrollment of approximately 53 patients across dose escalation and dose expansion phases,1 but actual enrollment reached 16 participants, and results were first posted on 2026-09-25.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.